Credit: NxStage Medical.

Medical products developer B. Braun Medical has entered into an agreement to purchase a bloodlines business from medical technology company NxStage Medical.

Operated under the Medisystems brand, the bloodlines business contains a portfolio of blood tubing solutions intended for the elimination of blood-air interfaces. The blood tubing products are called Streamline Long, Streamline Express and Streamline.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The business’s portfolio also contains a tubing product called Reverso, which allows easy blood flow reversal during treatment.

“The deal is subject to Federal Trade Commission approval and contingent upon the closing of the pending merger between NxStage Medical and a unit of Fresenius Medical.”

Braun expects the acquisition, which will expand the company’s dialysis product range, to facilitate better promotion of Streamline.

Braun Medical vice-president Sam Amory said: “We are pleased to add the Streamline bloodline to our dialysis product portfolio.

“Although we have been selling Streamline for many years, this acquisition will allow us to more broadly promote Streamline’s benefits as part of our transformative system of products, which includes the Dialog haemodialysis machine and the Diacap PRO dialyser.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The deal is subject to Federal Trade Commission approval and contingent upon the closing of the pending merger between NxStage Medical and a unit of Fresenius Medical.

Braun anticipates completing its acquisition of the bloodlines business this year.

The company develops, manufactures and markets new medical products and services for the healthcare market. It primarily focuses on renal therapies, infusion therapy and pain management.

It aims to eliminate preventable treatment errors and improve patient, clinician and environmental safety.

With more than 61,000 employees across 64 countries, B. Braun’s sister companies include B. Braun Interventional Systems, Aesculap and CAPS.